Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2012 Apr 21

PMID 22517990

Citations 101

Authors

Henri J L M Timmers

Clara C Chen

Jorge A Carrasquillo

Millie Whatley

Alexander Ling

Graeme Eisenhofer

Kathryn S King

Jyotsna U Rao

Robert A Wesley

Karen T Adams

Karel Pacak

Affiliations

Soon will be listed here.

Abstract

Background: Pheochromocytomas and paragangliomas (PPGLs) are rare tumors of the adrenal medulla and extra-adrenal sympathetic chromaffin tissues; their anatomical and functional imaging are critical to guiding treatment decisions. This study aimed to compare the sensitivity and specificity of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET/CT) for tumor localization and staging of PPGLs with that of conventional imaging by [(123)I]-metaiodobenzylguanidine single photon emission CT ((123)I-MIBG SPECT), CT, and magnetic resonance imaging (MRI).

Methods: A total of 216 patients (106 men, 110 women, aged 45.2 ± 14.9 years) with suspected PPGL underwent CT or MRI, (18)F-FDG PET/CT, and (123)I-MIBG SPECT/CT. Sensitivity and specificity were measured as endpoints and compared by the McNemar test, using two-sided P values only.

Results: Sixty (28%) of patients had nonmetastatic PPGL, 95 (44%) had metastatic PPGL, and 61 (28%) were PPGL negative. For nonmetastatic tumors, the sensitivity of (18)F-FDG was similar to that of (123)I-MIBG but less than that of CT/MRI (sensitivity of (18)F-FDG = 76.8%; of (123)I-MIBG = 75.0%; of CT/MRI = 95.7%; (18)F-FDG vs (123)I-MIBG: difference = 1.8%, 95% confidence interval [CI] = -14.8% to 14.8%, P = .210; (18)F-FDG vs CT/MRI: difference = 18.9%, 95% CI = 9.4% to 28.3%, P < .001). The specificity was 90.2% for (18)F-FDG, 91.8% for (123)I-MIBG, and 90.2% for CT/MRI. (18)F-FDG uptake was higher in succinate dehydrogenase complex- and von Hippel-Lindau syndrome-related tumors than in multiple endocrine neoplasia type 2 (MEN2) related tumors. For metastases, sensitivity was greater for (18)F-FDG and CT/MRI than for (123)I-MIBG (sensitivity of (18)F-FDG = 82.5%; of (123)I-MIBG = 50.0%; of CT/MRI = 74.4%; (18)F-FDG vs (123)I-MIBG: difference = 32.5%, 95% CI = 22.3% to 42.5%, P < .001; CT/MRI vs (123)I-MIBG: difference = 24.4%, 95% CI = 11.3% to 31.6%, P < .001). For bone metastases, (18)F-FDG was more sensitive than CT/MRI (sensitivity of (18)F-FDG = 93.7%; of CT/MRI = 76.7%; difference = 17.0%, 95% CI = 4.9% to 28.5%, P = .013).

Conclusions: Compared with (123)I-MIBG SPECT and CT/MRI, both considered gold standards for PPGL imaging, metastases were better detected by (18)F-FDG PET. (18)F-FDG PET provides a high specificity in patients with a biochemically established diagnosis of PPGL.

Citing Articles

Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study.

Takenaka J, Watanabe S, Abe T, Takeuchi S, Hirata K, Kimura R Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005979 PMC: 11858449. DOI: 10.3390/ph18020165.

Presentation of metastatic carotid body paraganglioma on F-18 FDG PET/CT: a rare disease.

Dulet M, Trivedi V, Datta D, Elhence P, Kumar R EJNMMI Rep. 2024; 8(1):20.

PMID: 38972915 PMC: 11228009. DOI: 10.1186/s41824-024-00211-x.

Case report: Rare case of a preoperatively diagnosed spermatic cord paraganglioma and literature review.

Hao Y, Li X, Xie J, He W, Wang C, Sun F Front Oncol. 2024; 14:1373727.

PMID: 38680861 PMC: 11047120. DOI: 10.3389/fonc.2024.1373727.

A retrospective study of paraganglioma of the urinary bladder and literature review.

Zhao Y, Zhang Z, Wang S, Wen J, Wang D, Ji Z Front Surg. 2024; 11:1348737.

PMID: 38645508 PMC: 11026576. DOI: 10.3389/fsurg.2024.1348737.

Imaging of Pheochromocytomas and Paragangliomas.

Timmers H, Taieb D, Pacak K, Lenders J Endocr Rev. 2024; 45(3):414-434.

PMID: 38206185 PMC: 11074798. DOI: 10.1210/endrev/bnae001.

References

Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P . 18FDG PET in oncology: the best and the worst (Review). Int J Oncol. 2006; 28(5):1249-61. View

Timmers H, Hadi M, Carrasquillo J, Chen C, Martiniova L, Whatley M . The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007; 48(10):1599-606. DOI: 10.2967/jnumed.107.042721. View

Burnichon N, Briere J, Libe R, Vescovo L, Riviere J, Tissier F . SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010; 19(15):3011-20. PMC: 2901140. DOI: 10.1093/hmg/ddq206. View

Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo F, Morange I . 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?. J Nucl Med. 2009; 50(5):711-7. DOI: 10.2967/jnumed.108.060731. View

Shulkin B, Thompson N, Shapiro B, Francis I, Sisson J . Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999; 212(1):35-41. DOI: 10.1148/radiology.212.1.r99jl3035. View

Kaji P, Carrasquillo J, Linehan W, Chen C, Eisenhofer G, Pinto P . The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007; 156(4):483-7. DOI: 10.1530/EJE-06-0712. View

Timmers H, Kozupa A, Chen C, Carrasquillo J, Ling A, Eisenhofer G . Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007; 25(16):2262-9. DOI: 10.1200/JCO.2006.09.6297. View

Bagheri B, Maurer A, Cone L, Doss M, Adler L . Characterization of the normal adrenal gland with 18F-FDG PET/CT. J Nucl Med. 2004; 45(8):1340-3. View

Fiebrich H, Brouwers A, Kerstens M, Pijl M, Kema I, de Jong J . 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine.... J Clin Endocrinol Metab. 2009; 94(10):3922-30. DOI: 10.1210/jc.2009-1054. View

10.

Kaelin W . Von Hippel-Lindau disease. Annu Rev Pathol. 2007; 2:145-73. DOI: 10.1146/annurev.pathol.2.010506.092049. View

11.

Dahia P, Ross K, Wright M, Hayashida C, Santagata S, Barontini M . A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005; 1(1):72-80. PMC: 1183527. DOI: 10.1371/journal.pgen.0010008. View

12.

Timmers H, Eisenhofer G, Carrasquillo J, Chen C, Whatley M, Ling A . Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009; 71(1):11-7. PMC: 2713382. DOI: 10.1111/j.1365-2265.2008.03496.x. View

13.

Mann G, Link J, Pham P, Pickett C, Byrd D, Kinahan P . [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006; 13(2):187-97. DOI: 10.1245/ASO.2006.04.022. View

14.

Lenders J, Pacak K, Walther M, Linehan W, Mannelli M, Friberg P . Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002; 287(11):1427-34. DOI: 10.1001/jama.287.11.1427. View

15.

Pauwels E, Sturm E, Bombardieri E, Cleton F, Stokkel M . Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol. 2000; 126(10):549-59. DOI: 10.1007/pl00008465. View

16.

Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I . Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002; 222(2):507-12. DOI: 10.1148/radiol.2222010622. View

17.

Neumann H, Bausch B, McWhinney S, Bender B, Gimm O, Franke G . Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002; 346(19):1459-66. DOI: 10.1056/NEJMoa020152. View

18.

Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B . Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009; 94(12):4757-67. PMC: 2795662. DOI: 10.1210/jc.2009-1248. View

19.

Gimenez-Roqueplo A, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher E . Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf). 2006; 65(6):699-705. DOI: 10.1111/j.1365-2265.2006.02714.x. View

20.

Pacak K, Eisenhofer G, Carrasquillo J, Chen C, Li S, Goldstein D . 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001; 38(1):6-8. DOI: 10.1161/01.hyp.38.1.6. View